Abstract
Molecular predictors of outcome are increasingly important in determining optimal therapy for myeloid neoplasms. Mutations in the spliceosomal genes (U2AF1 and SRSF2) predict for poor outcomes in myelodysplastic syndromes (MDS) and related diseases. We investigated the effect of hematopoietic cell transplant (HCT) on the negative prognostic impact of U2AF1 and SRSF2 mutations. In total, 122 patients with MDS (30%), acute myeloid leukemia (51%), myeloproliferative neoplasms (MPN) (11%), and MDS/MPN (8%) receiving a HCT from 2003 to 2012 were evaluated for mutations in U2AF1 and SRSF2 by direct sequencing. Median time of follow up was 24 months (range 0.46-110). SRSF2 mutations were detected in 11 (10%) patients and U2AF1 in 3 (3%) patients. There were no significant differences in baseline characteristics between mutated and wild-type (WT) patients. Patients carrying SRSF2 and U2AF1 mutations had similar overall survival (P = 0.84), relapse mortality (P = 0.50), and non-relapse mortality (P = 0.72) compared to WT patients. However, taking into account disease status and cytogenetics in a subset of AML patients, SRSF2 and U2AF1 mutations were associated with worse survival (HR 3.71, P = 0.035).
References
Oct 24, 2002·Blood·John C ByrdUNKNOWN Cancer and Leukemia Group B (CALGB 8461)
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
Nov 11, 2009·Blood·Kebede HusseinAyalew Tefferi
Nov 26, 2010·The New England Journal of Medicine·Ted A GooleyGeorge B McDonald
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Sep 3, 2011·Leukemia·V VisconteR V Tiu
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Dec 14, 2011·Nature Genetics·Timothy A GraubertMatthew J Walter
Jan 4, 2012·International Journal of Laboratory Hematology·P L Greenberg
Jan 27, 2012·Current Hematologic Malignancy Reports·Giovanni BarosiVittorio Rosti
Feb 11, 2012·Blood·Hideki MakishimaJaroslaw P Maciejewski
Mar 6, 2012·Blood·Felicitas TholMichael Heuser
Mar 16, 2012·The New England Journal of Medicine·Matthew J WalterTimothy A Graubert
Jul 10, 2012·Haematologica·Sarah Abu KarJaroslaw P Maciejewski
Jul 25, 2012·Blood·Valeria VisconteRamon V Tiu
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Sep 14, 2013·Blood·Elli PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Jun 2, 2014·Haematologica·Rafael Bejar
Aug 6, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael BejarBenjamin L Ebert
Sep 17, 2014·Blood·Rafael BejarBenjamin L Ebert
Citations
Nov 6, 2018·American Journal of Hematology·Andrew T KuykendallRami S Komrokji
Mar 15, 2019·Journal of Internal Medicine·M Tobiasson, A O Kittang
Feb 2, 2018·American Journal of Hematology·Ayalew TefferiMrinal M Patnaik
Jun 15, 2017·Annals of Hematology·Michael HeuserFelicitas Thol
Jan 13, 2018·Blood Cancer Journal·Caner SayginAnjali S Advani
Jul 24, 2020·Scientific Reports·Shujuan WangYanfang Liu
Jul 22, 2021·American Journal of Hematology·Juliane GrimmSebastian Schwind
Nov 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Rachel B Salit, H Joachim Deeg